Risk of alanine aminotransferase flare in patients with previous hepatitis B virus exposure on biological modifier therapies-A population-based study.
Jacky Chiu Leung HoJoyce W Y MakTerry C F YipHong Man LamTsz Yan ChengTsz On LamLai Shan TamMan Fai LawCarmen K M CheungSiew C NgVincent W S WongGrace L H WongPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
Our study further supports the current suggestion of prophylactic anti-viral before starting anti-CD20 in HBV-exposed patients. While other biological therapies appear to have a lower risk for ALT flare, this result needs further confirmation.